Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 plus atezolizumab as second-line treatment of biliary tract cancer and in combination or not with paclitaxel as second-line treatment of esophagogastric cancer
2018-003902-14Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of sirexatamab, atezolizumab and paclitaxel in biliary cancer, cholangiocarcinoma (CCA), gastroesophageal junction adenocarcinoma and 1 more (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective response rate. Started Jun 2019; status: terminated.
02
Drugs
sirexatamabatezolizumabpaclitaxel
03
Conditions
biliary cancercholangiocarcinoma (CCA)gastroesophageal junction adenocarcinomahepatobiliary neoplasm
Beyond the preview
Go deeper on 2018-003902-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003902-14.